+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin therapy for the metabolic syndrome: the evidence base



Statin therapy for the metabolic syndrome: the evidence base



Metabolic Syndrome and Related Disorders 7(5): 393-396




(PDF emailed within 0-6 h: $19.90)

Accession: 055911239

Download citation: RISBibTeXText

PMID: 19731996

DOI: 10.1089/met.2009.0705.edi


Related references

Managing the dyslipidemia of metabolic syndrome: beyond statin therapy. Metabolic Syndrome and Related Disorders 10(3): 159-160, 2012

Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?. Current Atherosclerosis Reports 13(1): 31-42, 2011

Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?. International Journal of Cardiology 110(2): 276-277, 2005

Benefit of adding pioglitazone to statin therapy in non-diabetic patients with the metabolic syndrome. Wmj 105(5): 22-25, 2006

Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. Journal of the American College of Cardiology 60(3): 216-223, 2012

Evidence for statin therapy in polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism 1(1): 15-22, 2010

Acute coronary syndrome and early statin therapy: What is the evidence?. HeartDrug 2(5): 246-250, September-October, 2002

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with metabolic syndrome. Diabetes 52(Supplement 1): A214, 2003

Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study. Circulation Journal 76(12): 2840-2847, 2013

Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model. Angiology 62(2): 144-154, 2011

Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease. Journal of Cardiovascular Pharmacology 56(3): 241-245, 2011

Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care 28(10): 2508-2513, 2005

Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opinion on PharmacoTherapy 12(9): 1429-1438, 2011

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Current Medical Research and Opinion 20(9): 1437-1445, 2004

Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocrine Practice 13(1): 11-16, 2007